Corporate Sites
https://www.takeda.com/
Patients Site
Contact in CT:
Important News and Information
Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations 04/27/2020
c/o Dawn Holcombe
dawnho@aol.com
33 Woodmar Circle South Windsor, CT 06074 (860) 305-4510
Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds